Predicting the development of levodopa-induced dyskinesias A presynaptic mechanism?
After chronic levodopa use, many patients with Parkinson disease (PD) develop involuntary movements. Whether disabling or minor, levodopa-induced dyskinesia (LID) constitutes an undesirable outcome calling for better treatment strategies. Options for managing LID include delaying its onset by combining a dopaminergic agonist with levodopa from the start 1 or symptomatic control using amantadine. However, fundamental questions about LID remain: by what mechanisms does it develop, and why don't all patients go on to experience LID after sustained levodopa exposure?
Most studies with animal models of parkinsonism have suggested that the extent of the nigrostriatal dopaminergic lesion governs the severity of LID. 2 Intermittent delivery of dopaminergic therapy may be another contributing factor, due to the short clearance half-life of available levodopa preparations and the rapid subsequent catabolism of dopamine. Pulsatile stimulation of dopamine receptors provides a plausible explanation for how LID might arise. This theory suggests that continuous dopaminergic stimulation (CDS) treatment strategies may avoid or even reverse LID. 3, 4 Evidence favoring CDS includes studies in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned nonhuman primates receiving a dopaminergic agonist either continuously (which did not result in LID) or intermittently (which did). 5 However, other investigations have led to different conclusions. Using the common marmoset model of parkinsonism, outcomes from 3 different dopaminergic drugs with equipotent antiparkinsonian effects were compared: apomorphine, levodopa, and pergolide (with clearance half-lives of approximately 40 minutes, 90 minutes, and 21 hours, respectively). 6 Unexpectedly, the regimen most effective at inducing LID was not the most pulsatile regimen, apomorphine; instead, it was levodopa. 6 Furthermore, dyskinesias induced by apomorphine developed to the same extent as those from the much longer-acting agonist pergolide. The implication is that levodopa must possess an additional property besides its short dopaminergic action to explain how it induces LID. Controversy as to the mechanisms behind LID will likely continue because investigation has yielded disparate findings. Since administration of levodopa to nonparkinsonian animals 2 or nonparkinsonian humans with functionally intact nigrostriatal circuitry 7 does not induce dyskinesias, loss of dopaminergic projections to the striatum would seem necessary for LID. However, not all clinical investigations have linked the risk for LID with the severity of parkinsonian symptomatology (which is, presumably, a correlate of diminished dopaminergic neurotransmission). One study investigating presynaptic dopaminergic innervation (through imaging striatal dopamine transporter) did not find support for an expected relationship between dopaminergic terminal loss and the development of LID. 8 Because the latter study was retrospective and involved a small patient group, the current report in Neurology ® by Hong et al. 9 takes on particular importance. These investigators carried out a longitudinal study of 127 patients with PD involving . At a mean of 3.4 years after starting treatment with levodopa and other PD medications, 35 patients (27.6%) had acquired dyskinesias. The authors questioned whether PET scan analysis at the time of diagnosis could anticipate the eventual development of LID. Using multivariate Cox proportional hazard modeling, they found that reduction in dopaminergic innervation of the total putamen (and its anterior and posterior regions) predicted the risk of dyskinesias.
This observational study brings presynaptic dopaminergic denervation into the forefront for explaining dyskinesia. The analysis of loss in regional striatal dopamine transporter uptake provides useful information for characterizing relationships between regional brain pathology and LID. However, this study does not offer a simple clinical message because of several confounding factors. For example, 68.6% of patients with LID and 73.9% of those without dyskinesias also were receiving a dopaminergic agonist, a drug class known to lessen the risk for developing LID. 1 A greater percentage of their patients with LID were women. The mean daily levodopa per-kg dose was also higher for patients with LID (24% greater), and their mean Unified Parkinson's Disease Rating Scale (UPDRS) score at diagnosis was 9 points more than in patients without LID. Though the authors did not investigate rate of change in parkinsonism, it may be that the LID group had a more aggressive disease since their duration of PD symptoms prior to PET scanning was the same but their UPDRS motor scores were 47% more than in patients without LID. These confounding factors make it difficult to conclude how important the presynaptic dopaminergic lesion is, by itself, for developing LID.
What makes LID happen appears to be a more complex tale of the brain's molecular biology mingling PD with levodopa. Screening for gene mutations and single nucleotide polymorphisms has highlighted several factors influencing the emergence of LID. 10 In addition, the neurocircuitry and neuropharmacology of LID implicate more than just presynaptic dopamine innervation in LID phenomenology. LID can be suppressed by blocking striatal outflow pathways one or more synapses downstream from the putamen. Pharmacologic interventions capable of suppressing LID experimentally include drugs acting on a variety of neurotransmitter and neuromodulatory systems, such as dopaminergic, glutamatergic (ionotropic and metabotropic), adenosinergic (A 2A ), a 2 -adrenergic, cannabinoid (CB 1 ), opioid (k and m), serotonergic (5HT-1A , -2A , and -1B ), histaminergic (H 3 ), and trace-amine-associated-1 receptors.
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Properly recognizing LID can be a challenge for researchers. Hong et al. 9 ascertained dyskinesia status by either a patient's report or a clinician's observations. However, even well-informed patients can be unaware of dyskinesias, and a brief clinic visit can miss dyskinesias evident at other times. Another potential problem is recognizing "latent" LID: patients may have developed the brain changes needed to enact LID, but their routine medication regimen may be dosed below the threshold necessary for unmasking them.
Levodopa, a drug that has revolutionized the management of PD over the past half century, continues to hold secrets and is far from a perfect therapy. Understanding risk factors for LID and for other motor fluctuations is just one of many challenges ahead for improving therapeutics with levodopa. The research community regularly adds new insights like the current study to the growing literature on LID.
